Serum uric acid in hypertensive patients with and without peripheral arterial disease

Atherosclerosis

Volumn 168, Issue 1, 2003, Pages 163-168

  Langlois, Michel ^a   De Bacquer, Dirk ^b   Duprez, Daniel ^b,c   De Buyzere, Marc ^b   Delanghe, Joris ^b   Blaton, Victor ^a  

^a General Hospital St Jan   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Atherosclerosis; Claudication; Hypertension; Peripheral vascular disease; Risk factors

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; INSULIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; AGED; ANKLE; ARTERY DISEASE; ARTICLE; BODY MASS; BRACHIAL ARTERY; CLAUDICATION; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENDER; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY FUNCTION; LEG; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PULSE PRESSURE; RISK FACTOR; SMOKING; TREADMILL; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

EID: 0038741991     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00093-5     Document Type: Article

References (36)

1. Ward H.J. Uric acid as an independent risk factor in the treatment of hypertension. Lancet. 352:1998;670-671.
2. Messerli F.H., Frohlich E.D., Dreslinsky G.R., Suarez D.H., Aristimuno G.G. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann. Intern. Med. 93:1980;817-821.
3. Facchini F., Chen Y.D.I., Hollenbeck C.B., Reaven G.M. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance and plasma uric acid concentration. J. Am. Med. Assoc. 266:1991;3008-3011.
4. García Puig J., Ruilope L.M. Uric acid as a cardiovascular risk factor in arterial hypertension. J. Hypertens. 17:1999;869-872.
5. Alderman M.H., Cohen H., Madhavan S., Kivlighn S. Serum uric acid and cardiovascular events in succesfully treated hypertensive patients. Hypertension. 34:1999;144-150.
6. Franse L.V., Pahor M., Di Bari M., et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J. Hypertens. 18:2000;1149-1154.
7. Verdecchia P., Schillaci G., Reboldi G., Santeusanio F., Porcellati C., Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA Study. Hypertension. 36:2000;1072-1078.
8. Alderman M.H. Serum uric acid as a cardiovascular risk factor for heart disease. Curr. Hypertens. Rep. 3:2001;184-189.
9. Fang J., Alderman M.H. Serum uric acid and cardiovascular mortality in the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. J. Am. Med. Assoc. 283:2000;2404-2410.
10. Culleton B.F., Larson M.G., Kannel W.B., Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann. Intern. Med. 131:1999;7-13.
11. Wannamethee S.G. Serum uric acid is not an independent risk factor for coronary heart disease. Curr. Hypertens. Rep. 3:2001;190-196.
12. Makin A., Lip G.Y., Silverman S., Beevers D.G. Peripheral vascular disease and hypertension: a forgotten association? J. Hum. Hypertens. 15:2001;447-454.
13. Criqui M.H., Denenberg J.O., Langer R.D., Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc. Med. 2:1997;221-226.
14. Hiatt W.R., Hirsch A.T., Regensteiner J.G., Brass E.P. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Circulation. 92:1995;614-621.
15. Leng G.C., Fowkes F.G., Lee A.J., Dunbar J., Housley E., Ruckley C.V. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Br. Med. J. 313:1996;1440-1444.
16. Newman A.B., Shemanski L., Manolio T.A., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler. Thromb. Vasc. Biol. 19:1999;538-545.
17. Duprez D., De Backer T., De Buyzere M., Clement D.L. Estimation of walking distance in intermittent claudication: need for standardization. Eur. Heart J. 20:1999;641-644.
18. International Society of Hypertension guidelines for the management of hypertension. J. Hypertens. 17:1999;151-183.
19. Remijnse-Tamerius H.C.M., Duprez D., De Buyzere M., Oeseburg B., Clement D.L. Why is training effective in the treatment of patients with intermittent claudication? Int. Angiol. 18:1999;103-112.
20. Regensteiner J., Gardner A., Hiatt W. Exercise testing and exercise rehabilitation for patients with peripheral arterial disease: status 1997. Vasc. Med. 2:1997;147-155.
21. Chandry H., Holland A., Dormandy J. Comparison of graded versus constant treadmill test protocols for quantifying intermittent claudication. Vasc. Med. 2:1997;93-97.
22. Gardner A., Skinner J.S., Cantwell B.W., Smith L.K. Progressive versus single-stage treadmill tests for evaluation of claudication. Med. Sci. Sports Exerc. 23:1991;402-408.
23. Ruilope L.M., García Puig J. Hyperuricemia and renal function. Curr. Hypertens. Rep. 3:2001;197-202.
24. Green H.J., Fraser I.G. Differential effects of exercise intensity on serum uric acid concentration. Med. Sci. Sports Exerc. 20:1988;55-59.
25. Langlois M., Duprez D., Delanghe J., De Buyzere M., Clement D.L. Vitamin C status is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation. 103:2001;1863-1868.
26. Ross R. Atherosclerosis - an inflammatory disease. New Engl. J. Med. 340:1999;115-126.
27. Cahan M.A., Montgomery P., Otis R.B., Clancy R., Flinn W., Gardner A. The effect of cigarette smoking on six-minute walk distance in patients with intermittent claudication. Angiology. 50:1999;537-546.
28. Lowe G.D., Fowkes F.G., Dawes J., Donnan P.T., Lennie S.E., Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation. 87:1993;1915-1920.
29. Leyva F., Anker S., Swan J.W., et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur. Heart J. 18:1997;858-865.
30. Anker S.D., Leyva F., Poole-Wilson P.A., Kox W.J., Stevenson J.C., Coats A.J. Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart. 78:1997;39-43.
31. Doehner W., Rauchhaus M., Florea V.G., et al. Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. Am. Heart J. 141:2001;792-799.
32. Bergstrand L. Femoral and coronary atherosclerosis in patients with hyperlipidemia. Arteriographic findings correlated to clinical and biochemical parameters. Acta Radiol. Suppl. 392:1994;1-27.
33. Maxwell A.J., Bruinsma K.A. Uric acid is closely related to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. J. Am. Coll. Cardiol. 38:2001;1850-1858.
34. Patetsios P., Song M., Shutze W.P., et al. Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am. J. Cardiol. 88:2001;188-191.
35. Nieto F.J., Iribarren C., Gross M.D., Comstock G.W., Cutler R.G. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 148:2000;131-139.
36. Bagnati M., Perugini C., Cau C., Bordone R., Albano E., Bellomo G. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem. J. 340:1999;143-152.